These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24413538)

  • 1. Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease.
    Sharma A; Bemis M; Desilets AR
    Am J Alzheimers Dis Other Demen; 2014 Aug; 29(5):409-14. PubMed ID: 24413538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study.
    Ohnuma T; Toda A; Kimoto A; Takebayashi Y; Higashiyama R; Tagata Y; Ito M; Ota T; Shibata N; Arai H
    Clin Interv Aging; 2016; 11():29-36. PubMed ID: 26811674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study.
    Torosyan N; Sethanandha C; Grill JD; Dilley ML; Lee J; Cummings JL; Ossinalde C; Silverman DH
    Exp Gerontol; 2018 Oct; 111():118-121. PubMed ID: 30006299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
    Reger MA; Henderson ST; Hale C; Cholerton B; Baker LD; Watson GS; Hyde K; Chapman D; Craft S
    Neurobiol Aging; 2004 Mar; 25(3):311-4. PubMed ID: 15123336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
    Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
    Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer's disease.
    Ota M; Matsuo J; Ishida I; Takano H; Yokoi Y; Hori H; Yoshida S; Ashida K; Nakamura K; Takahashi T; Kunugi H
    Neurosci Lett; 2019 Jan; 690():232-236. PubMed ID: 30367958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies.
    Avgerinos KI; Egan JM; Mattson MP; Kapogiannis D
    Ageing Res Rev; 2020 Mar; 58():101001. PubMed ID: 31870908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Beneficial effects of ketogenic diet for Alzheimer's disease management].
    Charlot A; Lernould A; Plus I; Zoll J
    Biol Aujourdhui; 2023; 217(3-4):253-263. PubMed ID: 38018953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Brief Review of Caprylidene (Axona) and Coconut Oil as Alternative Fuels in the Fight Against Alzheimer's Disease.
    Chintapenta M; Spence J; Kwon HI; Blaszczyk AT
    Consult Pharm; 2017 Dec; 32(12):748-751. PubMed ID: 29467067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medium-chain fatty acids for the prevention or treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Castro CB; Dias CB; Hillebrandt H; Sohrabi HR; Chatterjee P; Shah TM; Fuller SJ; Garg ML; Martins RN
    Nutr Rev; 2023 Aug; 81(9):1144-1162. PubMed ID: 36633304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention.
    Wu L; Zhang X; Zhao L
    J Neurosci; 2018 Jul; 38(30):6665-6681. PubMed ID: 29967007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypometabolism as a therapeutic target in Alzheimer's disease.
    Costantini LC; Barr LJ; Vogel JL; Henderson ST
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S16. PubMed ID: 19090989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease.
    Henderson ST; Morimoto BH; Cummings JL; Farlow MR; Walker J
    J Alzheimers Dis; 2020; 75(2):547-557. PubMed ID: 32310169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases.
    Jensen NJ; Wodschow HZ; Nilsson M; Rungby J
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease.
    Cunnane SC; Courchesne-Loyer A; St-Pierre V; Vandenberghe C; Pierotti T; Fortier M; Croteau E; Castellano CA
    Ann N Y Acad Sci; 2016 Mar; 1367(1):12-20. PubMed ID: 26766547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementation of Medium-Chain Triglycerides Combined with Docosahexaenoic Acid Inhibits Amyloid Beta Protein Deposition by Improving Brain Glucose Metabolism in APP/PS1 Mice.
    Wang Z; Zhang D; Cheng C; Lin Z; Zhou D; Sun Y; Li W; Yan J; Luo S; Qian Z; Li Z; Huang G
    Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, β-amyloid toxicity, and astrocyte function.
    Hertz L; Chen Y; Waagepetersen HS
    J Neurochem; 2015 Jul; 134(1):7-20. PubMed ID: 25832906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.
    Klosinski LP; Yao J; Yin F; Fonteh AN; Harrington MG; Christensen TA; Trushina E; Brinton RD
    EBioMedicine; 2015 Dec; 2(12):1888-904. PubMed ID: 26844268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer's Disease.
    Croteau E; Castellano CA; Richard MA; Fortier M; Nugent S; Lepage M; Duchesne S; Whittingstall K; Turcotte ÉE; Bocti C; Fülöp T; Cunnane SC
    J Alzheimers Dis; 2018; 64(2):551-561. PubMed ID: 29914035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling digestion, absorption, and ketogenesis after administration of tricaprilin formulations to humans.
    Li Z; Ramirez G; Tang R; Paul CKX; Nair M; Henderson S; Morimoto B; Liu J; Kaasgaard T; Boyd BJ; Wacker MG
    Eur J Pharm Biopharm; 2023 Jan; 182():41-52. PubMed ID: 36470522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.